Literature DB >> 18755930

When is a negative phase II trial truly negative?

Gordon D Rubenfeld, Edward Abraham.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18755930     DOI: 10.1164/rccm.200807-1136ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  6 in total

1.  Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury.

Authors:  Michael A Matthay; Roy G Brower; Shannon Carson; Ivor S Douglas; Mark Eisner; Duncan Hite; Steven Holets; Richard H Kallet; Kathleen D Liu; Neil MacIntyre; Marc Moss; David Schoenfeld; Jay Steingrub; B Taylor Thompson
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

2.  Outcomes and statistical power in adult critical care randomized trials.

Authors:  Michael O Harhay; Jason Wagner; Sarah J Ratcliffe; Rachel S Bronheim; Anand Gopal; Sydney Green; Elizabeth Cooney; Mark E Mikkelsen; Meeta Prasad Kerlin; Dylan S Small; Scott D Halpern
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

3.  Mortality is the only relevant outcome in ARDS: yes.

Authors:  Marc Moss
Journal:  Intensive Care Med       Date:  2014-12-05       Impact factor: 17.440

4.  I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.

Authors:  Daniel Clark Files; Michael A Matthay; Carolyn S Calfee; Neil R Aggarwal; Adam L Asare; Jeremy R Beitler; Paul A Berger; Ellen L Burnham; George Cimino; Melissa H Coleman; Alessio Crippa; Andrea Discacciati; Sheetal Gandotra; Kevin W Gibbs; Paul T Henderson; Caroline A G Ittner; Alejandra Jauregui; Kashif T Khan; Jonathan L Koff; Julie Lang; Mary LaRose; Joe Levitt; Ruixiao Lu; Jeffrey D McKeehan; Nuala J Meyer; Derek W Russell; Karl W Thomas; Martin Eklund; Laura J Esserman; Kathleen D Liu
Journal:  BMJ Open       Date:  2022-06-06       Impact factor: 3.006

5.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

Authors:  Michael A Matthay; Carolyn S Calfee; Hanjing Zhuo; B Taylor Thompson; Jennifer G Wilson; Joseph E Levitt; Angela J Rogers; Jeffrey E Gotts; Jeanine P Wiener-Kronish; Ednan K Bajwa; Michael P Donahoe; Bryan J McVerry; Luis A Ortiz; Matthew Exline; John W Christman; Jason Abbott; Kevin L Delucchi; Lizette Caballero; Melanie McMillan; David H McKenna; Kathleen D Liu
Journal:  Lancet Respir Med       Date:  2018-11-16       Impact factor: 30.700

6.  Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.

Authors:  Caroline Hauw-Berlemont; Miryam Mebarki; Philippe Menasché; Jérôme Larghero; Antoine Monsel; Nicholas Heming; Julien Mayaux; Otriv Nguekap Tchoumba; Jean-Luc Diehl; Alexandre Demoule; Djillali Annane; Clémence Marois; Sophie Demeret; Emmanuel Weiss; Guillaume Voiriot; Muriel Fartoukh; Jean-Michel Constantin; Bruno Mégarbane; Gaëtan Plantefève; Stéphanie Malard-Castagnet; Sonia Burrel; Michelle Rosenzwajg; Nicolas Tchitchek; Hélène Boucher-Pillet; Guillaume Churlaud; Audrey Cras; Camille Maheux; Chloé Pezzana; Mamadou Hassimiou Diallo; Jacques Ropers
Journal:  Crit Care       Date:  2022-02-21       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.